The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
 
 
 
 

Cardiovascular responses to increasing plasma concentrations of AQ-A 39 Cl, a new compound with negative chronotropic effects.

5,6-Dimethoxy-2-((3[(alpha-(3,4-dimethoxy) phenylethyl)-methylamino]propyl))-phthalimidine hydrochloride (AQ-A 39 Cl, in the following briefly called AQ-A 39) is a new compound with a structure similar to that of verapamil and which exhibits a specific bradycardic effect by a direct action on the sinus node. In nine anesthetized pigs the compound produced a dose-dependent decrease in heart rate up to 35%. For concentrations less than 1500 ng . ml-1, the drug exerted only minor effects on myocardial contractility (less than 5%), but for concentrations greater than 2000 ng . ml-1 negative inotropic properties became apparent and cardiac output decreased up to 25%, in spite of an increase in stroke volume. Left ventricular filling pressure and systemic vascular resistance were not affected. Myocardial O2-consumption also decreased dose-dependently up to 35%. The reduction in heart rate was not the only factor in determining the magnitude of this decrease as substantial decreases (25-30%) were also observed when, during drug administration, the heart rates were raised to 120 and 150 beats . min-1, respectively by means of coronary sinus pacing. The decrease in myocardial O2-consumption was reflected by decreases in both coronary blood flow and myocardial O2-extraction, while coronary vascular resistance did not change. The cardiovascular profile of AQ-A 39 indicated that, especially for arterial plasma concentrations lower than 1500 ng . ml-1, the drug may be useful in the treatment of tachycardias and in lowering myocardial O2-demand, without adverse effects on cardiovascular performance.[1]

References

 
WikiGenes - Universities